H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Abeona Therapeutics (ABEO) to $20 from $15 and keeps a Buy rating on the shares after the FDA approved the biologics license application for the company’s lead candidate, prademagene zamikeracel. The approval is on schedule with much higher than projected pricing and solid commercial plan, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics’ Promising Outlook: FDA Approval and Strategic Pricing of Zevaskyn Drive Buy Rating
- Abeona Therapeutics price target raised to $21 from $14 at Stifel
- Abeona approval does not change Krystal opportunity, says H.C. Wainwright
- Abeona Therapeutics Hosts Conference Call and Webcast
- Abeona Therapeutics announces FDA approval of Zevaskyn